SINOMED(SH:688108) Sou Hu Cai Jing·2025-08-21 09:56Company Overview - Sino Medical reported a total revenue of 240 million yuan for the first half of 2025, representing a year-on-year growth of 12.53% [1] - The net profit for the same period was 13.8416 million yuan, showing a significant increase of 296.54% compared to the previous year [1] - Earnings per share were 0.03 yuan, with a return on equity of 1.58% and operating cash flow per share of 0.1261 yuan [1] - The gross profit margin stood at 63.64% [1] Business Focus - Sino Medical, established in 2007, is located in the Tianjin Development Zone and specializes in the research, production, and sales of high-end interventional medical devices [1] - The company's product pipeline includes key areas of interventional treatment such as cardiovascular, cerebrovascular, and structural heart diseases [1] - The core product is the BuMA biodegradable drug-coated coronary stent system, which is designed and developed in-house and holds international intellectual property rights [1] Investment and Intellectual Property - Sino Medical has made investments in 7 companies and participated in 363 bidding projects [1] - The company holds 39 trademark registrations and 105 patents, along with 60 administrative licenses [1]